Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
2021 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Wiendl, H.; Gold, R. ; Berger, T.; Derfuss, T.; Linker, R. ; Mäurer, M. & Aktas, O. et al. (2021)
Therapeutic Advances in Neurological Disorders, 14 pp. 175628642110396. DOI: https://doi.org/10.1177/17562864211039648
Documents & Media
Details
- Authors Group
- for the ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG)
The authors list is uncomplete: - Authors
- Wiendl, Heinz; Gold, Ralf ; Berger, Thomas; Derfuss, Tobias; Linker, Ralf ; Mäurer, Mathias; Aktas, Orhan; Baum, Karl; Berghoff, Martin; Bittner, Stefan; Zipp, Frauke
- Abstract
- Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland).
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland). - Issue Date
- 2021
- Journal
- Therapeutic Advances in Neurological Disorders
- ISSN
- 1756-2864
- eISSN
- 1756-2864
- Language
- English